^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC

Published date:
11/25/2020
Excerpt:
In total, 3787 NSCLC samples were analyzed....five patients harboring genomic-positive but RNA and protein–negative ALK or ROS1 fusion who received crizotinib had PD within 1 to 3 months of therapy
DOI:
10.1016/j.jtho.2020.10.156